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Abstract: In Parkinson’s disease (PD) there is widespread accumulation in the brain of abnormal α-synuclein aggregates
forming intraneuronal Lewy bodies (LB). It is now well established that LB-type α-synuclein aggregates also occur in the
peripheral autonomic nervous system in PD, from where it has been speculated they may progressively spread to the
central nervous system through synaptically-connected brain networks and reach the substantia nigra to trigger herein
dopaminergic dysfunction/degeneration and subsequent parkinsonism. Supporting a pathogenic role for α-synuclein
aggregates we have previously shown that LB purified from postmortem PD brains promote α-synuclein pathology and
dopaminergic neurodegeneration when intracerebrally inoculated into wild-type mice. However, the pathogenic capacity
of PD-derived peripheral α-synuclein aggregates remains unknown. Here we addressed this question using purified
LB-type α-synuclein aggregates from postmortem PD stellate ganglia (SG), a paravertebral sympathetic ganglion that
exhibits consistent and conspicuous Lewy pathology in all PD patients. In contrast to our previous findings using nigral LB
extracts, intracerebral inoculation of SG-derived LB into mice did not trigger long-term nigrostriatal neurodegeneration
nor α-synuclein pathology. The differential pathogenic capacities of central- and peripheral-derived α-synuclein
aggregates appear independent of the absolute amount and basic biochemical properties of α-synuclein within these
aggregates and may rely instead on differences in α-synuclein conformation and/or yet unrecognized brain region-
specific intrinsic factors. Our results argue against a putative pathogenic capacity of peripheral α-synuclein aggregates to
promote α-synuclein pathology in the brain, propagate between neuronal networks or induce neurodegeneration.
Introduction
Brain pathology in Parkinson’s disease (PD) is characterized
by prominent loss of dopaminergic neurons from the
substantia nigra pars compacta (SNpc) and the presence in
affected brain regions of intraneuronal Lewy bodies (LB)
and Lewy neurites (LN) consisting mostly of aggregated
α-synuclein. At late stages of the disease, deposits of aggre-
gated α-synuclein are widely spread in the central nervous
system (CNS). In addition, it is now well established that
LB-type α-synuclein aggregates also occur in the peripheral
autonomic nervous system (pANS) [1, 8, 25]. It has been
proposed that Lewy pathology may actually start in the
periphery and progressively spread to the CNS through
synaptically-connected brain networks, driving neuronal
dysfunction and death along the way [9]. Supporting this
concept, most PD patients experience a premotor period
several years before the emergence of parkinsonism charac-
terized by a variety of non-motor symptoms driven by
neuronal damage in extranigral regions of the central and
peripheral autonomic nervous system [22]. Furthermore,
α-synuclein brain pathology can be triggered in experimen-
tal animals, including rodents and non-human primates, by
intracerebral, intramuscular, intragastrical or intravenous
inoculation of recombinant α-synuclein fibrils or brain
homogenates from affected mice and patients [5, 11, 13, 14,
16, 18–21]. Indeed, we have previously shown that intrani-
gral inoculation of α-synuclein-containing LB extracts
purified from the SNpc of PD brains promotes widespread
α-synuclein pathology and dopaminergic neurodegeneration
in recipient mice [20]. However, the pathogenic capacity of
PD-derived peripheral α-synuclein aggregates remains
unknown.
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Here we assessed for the first time the in vivo pathogenic
potential of peripheral α-synuclein aggregates by inoculat-
ing α-synuclein-containing LB extracts purified from post-
mortem stellate ganglia (SG) of PD patients into the SNpc
of wild-type mice. SG is a paravertebral sympathetic
ganglion that exhibits consistent and conspicuous Lewy
pathology in PD patients, but not in control subjects [7, 8,
17]. In fact, SG is one of the few peripheral tissues that in-
variably exhibits α-synuclein pathology in PD and the one
with the highest burden of pathological α-synuclein [8]. In
particular, abundant LB and LN-like structures immunore-
active for α-synuclein, phosphorylated α-synuclein and
ubiquitin are seen in the SG of PD patients, with a highest
density at the periphery of the ganglia [8]. Lewy pathology
in the SG is accompanied by neurodegenerative changes in
this ganglion, such as enlarged neurons with reduced tyro-
sine hydroxylase (TH) immunoreactivity, loss of pigmented
and non-pigmented neurons with increased cellularity and
formation of Nageotte nodules, as well as frequent micro-
glia/macrophage activation [8]. For the above reasons, here
we have chosen the SG to purify PD-linked peripheral
α-synuclein aggregates to assess their pathogenic potential
in vivo.
Methods
Purification of LB from human SG
Human fresh frozen postmortem SG samples from three
patients with sporadic PD and two non-PD control subjects
were obtained from the Neurological Tissue Bank, Biobanc
Hospital Clínic-IDIBAPS (see Table 1 for details). SG is a
sympathetic ganglion located in front of the neck of the
first rib (at the level of the 7th cervical vertebrae) formed
by the fusion of the inferior cervical and 1st thoracic (T1)
sympathetic ganglia. SG samples were homogenized in 9
vol (w/v) ice-cold MSE buffer (10 mM MOPS/KOH,
pH 7.4, 1 M sucrose, 1 mM EGTA, and 1 mM EDTA)
with protease inhibitor cocktail (Complete Mini; Boehrin-
ger Mannheim) with 12 strokes of a motor-driven glass/
teflon homogenizer. For LB purification, a sucrose step
gradient was prepared by overlaying 2.2 M with 1.4 M and
finally with 1.2 M sucrose in volume ratios of 3.5:8:8 (v/v),
as previously described [20]. The homogenate was layered
on the gradient and centrifuged at 160,000 x g for 3 h
using a SW32.1 rotor (Beckman). Twenty fractions of 500 μl
were collected from each gradient from top (fraction 1) to
bottom (fraction 20), and analyzed for the presence of
α-synuclein aggregates by filter retardation assay.
Filter retardation assay
This technique was performed as previously described [20].
Briefly, after heating at 100 °C for 5 min, samples (70 mg)
were diluted in 200 μl of migration buffer (25 mM Tris-
HClBase, 200 mM glycine, SDS 1%) and filtered through a
cellulose acetate membrane (Schleicher & Schuell; 0.2 μm
pore size) using a Minifold-1 Dot-Blot System (Schleicher &
Schuell). Membranes were saturated in 5% dried skimmed
milk in phosphate-buffereld saline (PBS) and probed with
human α-synuclein antibody (see below for details). Appro-
priate secondary antibodies coupled to peroxidase were
revealed using a Super Signal West Pico Chemiluminescent
kit (Pierce). Chemiluminescence images were acquired
using the ImageQuant RT ECL Imager (GE Healthcare).
Immunoblot
SG-derived fractions were resolved by SDS-PAGE on 15%
polyacrylamide gels and electrotransferred onto nitrocellu-
lose membranes (GE Healthcare, #10401196), then blocked
in 5% non-fat milk powder in tris-buffered saline (TBS)
containing 0.1% tween-20 (TBS-T) for 1 h at room
temperature (RT) and incubated overnight at 4 °C with a
mouse anti-human α-synuclein antibody (1/500 in 4% bo-
vine serum albumin/TBS-T, Thermo Scientific, #MS1572).
Incubation with the anti-mouse secondary antibody
coupled to horseradish peroxidase (1:2000 in 5% non-fat
milk powder/TBS-T; Amersham Biosciences, #NXA931)
was performed at RT for 1 h, followed by repeated washings
with TBS-T. Immunoreactive bands were visualized using
SuperSignal Femto Chemiluminescent Substrate (Pierce,
#34096) according to the manufacturer’s instructions on an
ImageQuant RT ECL imaging system (GE Healthcare).
Enzyme-linked immunosorbent assay
Total protein concentrations in the different sucrose ex-
tracts were determined using the bicinchoninic acid assay
(#23227; Thermo Scientific, Waltham, MA). Samples were
bath sonicated for 5 min, diluted to 20 μg/ml of total
Table 1 Human sample information
Case Gender Age at death (years) Diagnosis aSyn in SG PMI
PD#1 Female 84 PD stage 5 positive 4.5
PD#2 Female 81 PD stage 5 positive 6.5
PD#3 Male 68 PD stage 4 positive 9.33
Ctrl#1 Female 89 AD VI C+ TDP amygdala negative 4.25
Ctrl#2 Male 88 AD IV C + thalamic infarct negative 18.25
PD Parkinson’s disease, AD Alzheimer type pathology according to Braak staging (I-VI) and CERAD criteria (A-C), TDP Transactive response DNA binding protein
43 kDa, aSyn α-synuclein, SG stellate ganglion, PMI postmortem interval (hours)
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protein and analyzed in triplicates for total α-synuclein pro-
tein levels with a specific enzyme-linked immunosorbent
assay (ELISA) kit against human α-synuclein (Life Tech-
nologies, #KHB0061) according to the manufacturer’s
instructions.
Stereotactic inoculations
For stereotactic inoculations, LB-containing SG fractions
from the three PD patients were first mixed together in
the same proportion (PD #1, fractions 17 and 18; PD #2,
fraction 18; PD #3, fractions 16 and 17; see Fig. 1). Control
animals were inoculated with a mixture of equivalent frac-
tions obtained from SG of two age-matched human
control subjects lacking α-synuclein pathology (Ctrl #1,
fraction 17; Ctrl #2, fractions 16 and 17; see Fig. 1). An
additional control group was injected with the corre-
sponding buffer (vehicle) obtained from a sucrose gradient
purification performed without the addition of any human
tissue sample. In all cases, samples were bath-sonicated
for 5 min prior to the in vivo inoculations. Wild-type
C57BL/6 mice (3 months old) received 2 μl of either LB-
SG fractions, control-derived fractions, or appropriate
buffer (vehicle) by stereotactic delivery to the region im-
mediately above the right substantia nigra (− 2.9 mm AP,
1.3 mm L and − 4.5 mm DV) at a flow rate of 0.4 μl/min.
Animals were euthanized at either 24 h or 6 months after
injection and the position of the 30-gauge needle was
determined histologically.
Cylinder behavioral test
Mice were tested for left and right forepaw use with the cy-
linder test one week before surgery (to establish the basal
conditions for each animal) and at 6 months post-surgery.
For the performance of the cylinder test, mice were first
allowed to habituate to the experimental room for at least
one hour before each test. Then, mice were put in a glass
cylinder and the total number of left and right forepaw
touches performed within 5 min was counted. Data are pre-
sented as the percentage of contralateral forepaw use with
respect to total forepaw use (contralateral + ipsilateral). All
behavioral tests were performed during the light cycle by
an investigator blinded to the experimental groups.
Immunohistochemistry
Twenty-four hours or six months after stereotactic inocula-
tions, mice were euthanized by perfusion with 4% PFA and
their brains were processed for immunohistochemical
analyses. Immunostaining was performed on 20 μm-thick
free-floating sections incubated with different primary anti-
bodies (see below) for 24 h at 4 °C. Biotinylated secondary
antibodies, followed by signal amplification using the
avidin-biotin complex (ABC) method, were used. Immuno-
staining was revealed using 3,3′-diaminobenzidine tetrahy-
drochloride (DAB, Sigma Aldrich, #D5905-50TAB). When
mouse secondary antibodies were required, a Vector M.O.M
Immunodetection kit (Vector Laboratories, #BMK2202) was
used, according to the manufacturer’s instructions. The fol-
lowing antibodies were used: Tyrosine Hydroxylase (1/1000,
Calbiochem, #657012), human α-synuclein Ab-2 (clone
syn211, 1/250, Thermo Scientific, #MS-1572), α-synuclein
(1/1000, BD Transduction Laboratories, #610786), phos-
phorylated α-synuclein (phospho S129, 1/750, Abcam,
#2014–1), Ionized calcium binding adaptor molecule 1
(Iba1, 1/1000, Wako Pure Chemical Industries, #019–
19,741) and Glial Fibrillary Acid Protein (GFAP, 1/1000,
Sigma-Aldrich, #G3893).
Quantitative morphology
Nigrostriatal integrity: the total number of TH-positive
SNpc neurons was assessed by stereology with the optical
fractionator method in regularly spaced (every sixth)
20 μm-thick sections spanning the entire SNpc using
StereoInvestigator software (MBF Bioscience). Striatal
TH innervation was assessed by optical densitometry in
regularly spaced 20 μm-thick sections corresponding to
different striatal anatomical levels using Sigma Scan.
α-Synuclein pathology: (1) the total number of α-
synuclein-positive neurons in the SNpc was assessed by ste-
reology, as above; (2) the total number of hyperphosphory-
lated α-synuclein (pSyn)-positive neurons in the SNpc was
manually assessed under light microscopy in four sections
spanning the entire SN; (3) pSyn at regional level was
assessed by optical densitometry using the ImageJ software
in pSyn-immunostained sections scanned with an Epson
Perfection V750 PRO scanner (Long Beach, CA); (4)
intracellular α-synuclein levels were assessed by optical
densitometry at cellular level using Sigma Scan in
transmitted-light microscopy images of α-synuclein-
positive cells from the SNpc (~ 650 neurons per group,
randomly selected among the different animals).
Neuroinflammation: for inflammatory reaction assess-
ment, microglia and astrocyte density were estimated by
OD at regional level in Iba1- and GFAP-immunostained
sections, respectively, using Sigma Scan software. All
analyses were performed blinded to the researcher.
Proteinase K digestion
Twenty-micrometer-thick sections were washed with TBS
and incubated in proteinase K (PK; Invitrogen, Carlsbad,
CA; 1 μg/ml in TBS) at RT for 10 min. The sections were
then washed in TBS and immunostained for α-synuclein
as indicated above.
Statistical analysis
All values are expressed as the mean ± standard error of
the mean (SEM). Statistical comparisons between control-
injected and LB-SG-injected animals were performed with
SigmaStat software (v4, Systat Software Inc., USA) using
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two-tailed t-test, Mann-Whitney rank sum test or one-
way ANOVA, as appropriate. Selection of the pertinent
statistical test for each experiment was determined after
formally testing for normality. In all analyses, the null
hypothesis was rejected at the 0.05 level.
Results
Purification of SG LB from PD patients
Peripheral LB-containing fractions were obtained from
freshly frozen postmortem SG tissue derived from 3 pa-
tients with sporadic PD exhibiting abundant LB pathology
at neuropathological examination (Fig. 1a). In the SG of
these patients, Lewy pathology appeared in the form of
α-synuclein immunopositive LB-like structures and LN
(Fig. 1a), as previously described [8]. Two main types of
LB-like structures could be observed in these samples: (i)
filamentous LB with a dense central core and radiating fila-
ments, similar to the classical LB found in the SN, with a
stronger ring-like α-synuclein immunoreactivity at the per-
iphery than in the cores (Fig. 1a) and (ii) ill-defined struc-
tures that were diffusely immunoreactive for α-synuclein.
These structures were previously found to contain also
hyperphosphorylated pathological forms of α-synuclein
(phosphorylated at serine 129) and ubiquitin, two major
components of LB [8]. In contrast, no α-synuclein path-
ology was observed in the SG of age-matched non-PD con-
trol subjects (Additional file 1: Figure S1). LB purification
from PD-derived SG samples was achieved by sucrose gra-
dient fractionation, as previously done for SNpc-derived LB
purification [20]. Briefly, SG samples were homogenized
and layered on the top of a sucrose gradient (from 1.0 M to
2.2 M), with LB-containing fractions being recovered at the
1.4/2.2 M interface after ultracentrifugation (Fig. 1b). To
identify LB-containing fractions, all recovered sucrose gra-
dient fractions (N = 20) were screened by filter retardation
assay for the presence of insoluble α-synuclein aggregates
(Fig. 1b), as previously validated [20]. Using this biochem-
ical assay, LB fractions containing insoluble α-synuclein
aggregates were found within fractions 16 to 18, as ex-
pected (Fig. 1b). None of the fractions derived from SG
samples of non-PD control subjects contained α-synuclein
aggregates (Fig. 1b). The presence of α-synuclein in PD-
derived, but not control-derived, SG fractions was further
confirmed by immunoblot (Fig. 1c). For stereotactic inoc-
ulations to mice, LB-containing SG fractions from the 3
PD patients were mixed together in the same proportion,
as follows: PD #1, fractions 17 and 18; PD #2, fraction 18;
PD #3, fractions 16 and 17 (Fig. 1b). Prior to inoculation to
mice, this mixture (called “LB-SG” henceforth) was bath-
sonicated for 5 min, to disrupt the aggregates into fibrillar
fragments of different sizes, as in our previous study using
SNpc-derived LB fractions [20]. Quantifications by ELISA
indicated that this mix contained 17.27 ± 2.23 ng of
α-synuclein per milligram of total protein, similar to the ~
Fig. 1 Purification of peripheral Lewy bodies (LB) from stellate ganglion (SG) of PD patients. a Schematic representation of SG localization and
representative photomicrograph of α-synuclein pathology by immunohistochemistry (in brown) in the SG of one of the PD patients used in this study,
as previously reported [8]. Arrows, LB-like structures; asterisks, Lewy neurites. b Left, schematic representation of the sucrose gradient fractionation
procedure used to purify LB-containing fractions from freshly frozen human SG tissue. Right, filter retardation assay probed with a human α-synuclein
antibody to assess the presence of insoluble α-synuclein aggregates in the different fractions obtained by sucrose gradient fractionation from the SG
of three sporadic PD patients and two non-PD control (Ctrl) subjects. Rectangles indicate the fractions selected to prepare the mixture used
for inoculations. c Immunoblot levels of human α-synuclein in fractions 16 to 18 (corresponding to the 1.4/2.2 M interface) from PD patients
and non-PD control subjects
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15 ng/mg previously obtained from SNpc-derived LB
fractions [20]. Control animals were injected with
equivalent fractions obtained from SG of age-matched
non-PD human control subjects lacking α-synuclein path-
ology (Fig. 1b, c). An additional control group was injected
with the corresponding buffer (vehicle) obtained from a su-
crose gradient purification performed without the addition
of any human tissue sample.
Lack of nigrostriatal degeneration in mice inoculated with
SG-derived LB extracts
To determine the potential pathogenic effects of periph-
eral α-synuclein aggregates from PD patients, adult wild-
type C57BL6 mice received single unilateral stereotaxic
inoculations (2 μl) of either LB-SG fractions, control-
derived fractions, or vehicle immediately above the right
SNpc (Fig. 2a), as we have previously done for SNpc-
derived LB fractions [20]. Six months after inoculation,
all animal groups were subjected to behavioral and
histological analyses. This time-frame was chosen based
on previous studies indicating that a pathogenic effect of
either synthetic recombinant α-synuclein pre-formed fibrils
or SNpc-derived LB extracts from PD brains can already
be observed by 3–4 months post-inoculation to mice
[13, 20]. First, we assessed motor ability in LB-SG-
injected mice using the cylinder test, which allows
asymmetrical alterations in nigrostriatal dopaminergic
function to be detected in unilaterally-injected mice
[15]. Using this test, we did not observe any contralat-
eral forepaw hypokinesia in LB-SG-injected mice, as in-
dicated by an equivalent use of both forepaws in these
animals, similar to control-injected groups (Fig. 2b). We
next assessed the integrity of the dopaminergic nigrostria-
tal system in these animals, at the level of both SNpc cell
bodies and striatal axon terminals, by stereological cell
counts of dopaminergic TH-positive SNpc neurons and by
optical densitometry of striatal dopaminergic TH-positive fi-
bers, respectively. Consistent with the lack of motor impair-
ment, no nigrostriatal degeneration was observed in LB-SG-
injected animals at 6 months post-inoculation, as indicated
by a preservation of both SNpc dopaminergic cell bodies
and striatal dopaminergic fibers in these animals (Fig. 2c-d).
In addition, no evidence of ongoing neuroinflammatory
changes was observed in these animals, as shown by a lack
Fig. 2 Integrity of the nigrostriatal pathway in LB-SG-injected mice. a Schematic diagram indicating the site of nigral stereotactic inoculations to
mice. b Contralateral forepaw use, as assessed by the cylinder test, in mice injected with control- and PD-derived LB-SG fractions at 6 months
post-inoculation. Ctrl: n = 8; mean = 47.87; SD = 9.128; SEM = 3.227; LB-SG: n = 12; mean = 52.62; SD = 7.929; SEM = 2.289; p = 0.23, two-tailed t-test.
c Left, representative photomicrographs of ipsilateral tyrosine hydroxylase (TH)-positive substantia nigra pars compacta (SNpc, outlined in red)
neurons (dark brown; thionin staining in purple) from vehicle-, Ctrl- and LB-SG-injected animals, at 6 months post-inoculation. Right, quantification
of ipsilateral TH-positive SNpc neurons by stereology in vehicle-, Ctrl- and LB-SG-injected mice, at 6 months post-inoculations. Vehicle: n= 9; mean =
5736.66; SD = 879.61; SEM= 293.20; Ctrl: n= 7; mean = 5198.57; SD = 1282.38; SEM= 484.69; LB-SG: n = 9; mean = 5520; SD = 1219.34; SEM= 406; p= 0.644,
one-way ANOVA. d Left, representative photomicrographs of TH-positive striatal terminals (in brown) from vehicle-, Ctrl- and LB-SG-injected animals at
6 months post-inoculation (asterisk indicate injected hemisphere). Right, quantification of ipsilateral TH-positive striatal terminals by optical densitometry
(OD) in Ctrl- and LB-SG-injected mice, relative to vehicle-injected animals, at 6 months post-inoculations. Ctrl: n = 8; mean = 96.86; SD = 9.52;
SEM = 3.37; LB-SG: n = 11; mean = 97.39; SD = 18; SEM = 5.427; p = 0.836, Mann-Whitney rank sum test. e Quantification of microglial Iba1 and
astrocytic GFAP reactions by OD in the ipsilateral SN of Ctrl- and LB-SG-injected mice, relative to vehicle-injected animals, at 6 months post-in-
oculations. For Iba1, Ctrl: n = 8; mean = 119.8; SD = 16.04, SEM = 5.671; LB-SG: n = 11; mean = 120.7; SD = 12.56; SEM = 3.788; p = 0.773 Mann-Whitney
rank sum test. For GFAP, Ctrl: n = 8; mean = 99.77; SD = 14.3; SEM = 5.055; LB-SG: n = 12, mean = 113.7; SD = 17.67; SEM = 5.101; p = 0.08, two-
tailed t-test. In all panels, histograms represent average ± standard error of the mean (SEM). Vehicle-injected mice, n = 9–11. Scale bars, 500 μm
(c) and 1 mm (d)
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of microglial and astrocytic reaction in their SNpc (Fig. 2e).
Overall, our results indicate that, in contrast to what we
have previously seen for SNpc-derived LB extracts [20], per-
ipheral LB-SG extracts are not able to trigger nigrostriatal
neurodegeneration when injected to mice.
Lack of α-synuclein pathology in mice inoculated with
SG-derived LB extracts
We next determined whether intranigral inoculation of
SG-derived LB extracts could trigger α-synuclein path-
ology in injected animals, as we have previously seen for
SNpc-derived LB extracts [20]. Using an antibody that
recognizes human but not murine α-synuclein, we found
that exogenously inoculated SG-linked human α-synuclein
was internalized by host murine SNpc neurons by 24 h
post-injection (Fig. 3a). At this time-point, exogenous hu-
man α-synuclein was detected in LB-SG-injected mice, but
not in control-injected animals, as a punctate, inclusion-
like immunolabeling within the cytoplasm and along the
processes of murine host cells (Fig. 3a). No exogenous
human α-synuclein immunosignal was detected in LB-SG-
inoculated animals by 6 months post-inoculation.
Because we previously found that inoculation of SNpc-
derived LB extracts from PD patients to mice triggered
the pathological conversion and intracellular accumula-
tion of endogenous murine α-synuclein [20], we next
assessed whether injection of LB-SG fractions resulted in
a similar pathogenic effect. Using an antibody that rec-
ognizes murine α-synuclein, we assessed first by stere-
ology the number of α-synuclein-immunopositive neurons
in the SNpc of LB-SG-injected mice at 6 months
post-inoculation. No differences were found in the
number of SNpc α-synuclein-positive neurons between
LB-SG- and control-injected animals (Fig. 3b). Similarly,
no differences were found in the intracellular levels of
α-synuclein, assessed by optical densitometry, between
LB-SG- and control-injected animals at 6 months (Fig. 3c).
In the absence of changes in α-synuclein levels, we
next assessed whether endogenous α-synuclein in LB-
SG-injected mice might have adopted a pathological
Fig. 3 Lack of α-synuclein pathology in LB-SG-injected mice. a Immunohistochemistry of human α-synuclein (hSyn, in brown; thionin staining in
purple) in the SNpc of LB-SG-injected mice at 24 h post-inoculation. b Left, representative photomicrographs of endogenous murine α-synuclein
immunostaining (in brown) in the SN of Ctrl- and LB-SG-injected animals at 6 months post-inoculation. Right, number of α-synuclein-immunopositive
neurons in the ipsilateral SNpc of Ctrl- and LB-SG-injected mice, relative to vehicle-injected animals, at 6 months post-inoculations. Ctrl: n = 5; mean =
119.8; SD = 29.38; SEM = 13.14; LB-SG: n = 9; mean = 89.14; SD = 27.94; SEM = 9.313; p = 0.0768, two-tailed t-test. c Quantification of intracellular levels of
endogenous murine α-synuclein within ipsilateral SNpc neurons by optical densitometry (OD) in Ctrl- and LB-SG-injected mice, relative to vehicle-
injected animals, at 6 months post-inoculations. Ctrl: n = 645; mean = 109.3; SD = 37.06; SEM = 1.459; LB-SG: n = 603; mean = 110.8; SD = 34.27;
SEM = 1.396; p = 0.32, Mann-Whitney rank sum test. d Quantification of regional levels of endogenous murine α-synuclein by OD in the ipsilateral SN of
Ctrl- and LB-SG-injected mice at 6 months post-inoculations, relative to vehicle-injected animals, after proteinase K (PK) digestion (1 μg/ml for 10 min).
Ctrl: n = 6; mean = 106.5; SD = 15.82; SEM = 6.458; LB-SG: n = 12; mean = 114.6; SD = 14.61; SEM = 4.218; p = 0.2959, two-tailed t-test. e Number
of phosphorylated α-synuclein (pSyn)-immunopositive neurons in the ipsilateral SNpc of Ctrl- and LB-SG-injected mice, relative to vehicle-injected
animals, at 6 months post-inoculations. Ctrl: n = 8; mean = 173.9; SD = 85.39; SEM = 30.19; LS-SG: n = 10; mean = 145.7; SD = 30.83; SEM = 9.749,
p = 0.3435, two-tailed t-test. f Quantification of regional levels of pSyn by OD in the striatum and neocortical areas (i.e., cingulate, motor, and
somatosensory cortices) of Ctrl- and LB-SG-injected mice, relative to vehicle-injected animals, at 6 months post-inoculations. For striatum, Ctrl:
n = 7; mean = 106.1; SD = 10.69; SEM = 4.041; LB-SG: n = 10; mean = 101.5; SD = 13.6; SEM = 4.3; p = 0.47, two-tailed t-test. For cortex, Ctrl: n = 7;
mean = 106.9; SD = 16.15; SEM = 6.105; LB-SG: n = 10; mean = 104.9; SD = 12.59; SEM = 3.981; p = 0.773, two-tailed t-test. In all panels, histograms
represent average ± standard error of the mean (SEM). Vehicle-injected mice, n = 8–10. Scale bars, 30 μm (a) and 500 μm (b)
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insoluble/aggregated beta-sheet conformation resistant
to proteinase K (PK) digestion, as we have previously
seen for SNpc-derived LB extracts [20]. Ruling out this
possibility, no differences were found in the susceptibility
of α-synuclein to PK digestion (1μg/ml for 10 min) be-
tween LB-SG- and control-injected animals at 6 months
(Fig. 3d). Further excluding a pathological conversion of
α-synuclein in LB-SG-injected mice, no changes in hyper-
phosphorylated pathological forms of α-synuclein were
found between LB-SG- and control-injected animals at
6 months (Fig. 3e-f). LB-SG- and control-injected animals
exhibited equivalent levels of pSyn, both at the site of in-
jection (i.e. SNpc, Fig. 3e) and in distant anatomically con-
nected brain regions (i.e. striatum and neocortical areas,
Fig. 3f). Overall, these results indicate that, in contrast to
nigral LB extracts [20], peripheral LB-SG extracts are not
able to trigger long-term α-synuclein pathology in mice.
Discussion
This study assessed the pathogenic potential of periph-
eral α-synuclein aggregates from PD patients. In contrast
to our previous observation using nigral-derived LB ex-
tracts [20], peripheral α-synuclein aggregates from SG
did not produce any pathologic effect when inoculated
into the brain of recipient wild-type mice, up to 6 months
post-injection. While exogenous human α-synuclein
from SNpc- and SG-derived LB extracts were both
quickly internalized by host murine SNpc neurons, only
animals receiving SNpc-derived LB extracts exhibited
PD-like pathology [20]. Indeed, in previous experiments,
animals injected with SNpc-derived LB extracts exhib-
ited nigrostriatal neurodegeneration and widespread α-
synuclein pathology by 4 months post-inoculation [20],
while none of which was observed in LB-SG-injected
mice at 6 months. The differences in pathogenicity be-
tween SNpc- and SG-derived extracts cannot be attrib-
uted to methodological issues, as both studies were
performed in an identical manner, including the intracere-
bral site of injection (i.e. SNpc) [20]. Both SNpc and SG
LB fractions were purified using the same sucrose gradient
fractionation method and the amount of total α-synuclein
recovered in these fractions was comparable (~ 15 ng/mg
vs ~ 17 ng/mg, respectively, as quantified by ELISA). In
addition, the distribution pattern of α-synuclein aggre-
gates, revealed by filter retardation assay, was equivalent
between nigral and SG LB fractions, corresponding in
both studies to recovered fractions #16–18. The differen-
tial pathogenicity did not result either from the presence
of a putative pathogenic factor other than α-synuclein
specifically within nigral-derived LB fractions, since the
presence of α-synuclein in these fractions was an abso-
lute requirement for their pathogenic effect [20]. The
differential pathogenicity between nigral and SG LB
fractions might be linked to differences in α-synuclein
conformation within these fractions and/or to yet
unrecognized region-specific intrinsic factors. Support-
ing this concept, crosslinking experiments have shown
that endogenous α-synuclein species are different be-
tween human brain and human small intestine [4].
Along this line, a previous study in A53T α-synuclein-
overexpressing transgenic mice reported that α-synuclein
oligomers obtained from different CNS regions exhibited
differential pathogenic capacities in vitro, in terms of pro-
moting α-synuclein amyloid fibril formation and neuro-
toxicity, despite sharing similar biochemical properties
[26]. It has also been recently revealed the existence of dif-
ferent strains of α-synuclein able to adopt different struc-
tural conformations that cause distinct histopathological
and behavioral phenotypes when injected into experimen-
tal animals [19]. In this context, SG LB fractions might
need further maturation (e.g. conformation changes,
protein interactions, further processing and/or additional
post-translational modifications beyond phosphorylation)
to acquire pathogenic characteristics identical to those ori-
ginating from SNpc. Alternatively, SG LB extracts might
just be slower in triggering α-synuclein pathology and thus
require longer incubation times than SNpc-derived α-
synuclein aggregates to produce pathology. Further studies
to identify the exact composition and structure of PD-
linked α-synuclein aggregates from different areas of CNS
and peripheral nervous system (PNS) should shed light on
this matter.
Our results indicate that peripheral α-synuclein aggre-
gates, in particular those derived from the SG, lack the
capacity to promote α-synuclein pathology in the brain,
propagate between neuronal networks or induce neuro-
degeneration. This observation argues against one of the
currently prevalent pathogenic hypothesis of cell-to-cell
transmission of α-synuclein from the periphery to the
CNS [2]. However, the interpretation of our results needs
some caution. In our study, we have chosen the SG as per-
ipheral tissue because the SG is the peripheral structure
that exhibits the highest burden of α-synuclein pathology
and it does so invariably in all PD patients, but not control
subjects [8]. However, it is possible that α-synuclein aggre-
gates from other peripheral tissues might behave differ-
ently from a pathogenic point of view and, therefore, our
results might not be generalized to all peripheral struc-
tures. This question could be addressed in subsequent
studies by injecting α-synuclein aggregates derived from
other peripheral regions. For instance, due to its accessi-
bility, the gastrointestinal tract has been proposed as one
of the potential earliest sites of α-synuclein pathology
from where α-synuclein aggregates, initiated by exposure
to a putative pathogen or infectious agent, could spread
retrogradely to the brain through vagal nerve connections
[3, 8–12, 23]. It appears, however, that α-synuclein can
also be transported anterogradely from the brain to the
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stomach [27], raising the question as to whether periph-
eral α-synuclein aggregates really precede brain pathology
in PD or may instead occur concomitantly or even follow
CNS involvement [24].
While we found here that peripheral α-synuclein aggre-
gates from SG are not pathogenic when injected into the
brain, the presence of α-synuclein accumlation in periph-
eral tissue is often associated with peripheral autonomic
denervation [8, 29], thereby suggesting a potential patho-
genic effect of these aggregates in the periphery. Whether
these pathological alterations in peripheral tissue are actu-
ally caused by the presence of α-synuclein remains to be
determined. Because here we used postmortem SG sam-
ples derived from late PD stages, it is also possible that per-
ipheral α-synuclein aggregates from earlier disease stages
might exhibit different pathogenic capacity. This question
could be eventually tested using peripheral α-synuclein ag-
gregates from early manifest or even pre-motor PD sub-
jects, such as those with idiopathic REM sleep behavior
disorder [23, 28] or incidental Lewy body disease subjects
[1, 6]. However, our previous results using SNpc-derived
LB extracts demonstrated that samples derived from late
stages of the disease can actually be pathogenic [20].
Conclusions
Overall, here we demonstrate that, in contrast to CNS-
derived LB [20], peripheral LB-type α-synuclein aggre-
gates from PD patients are not pathogenic when injected
to mice. The differential pathogenic capacity of CNS-
and PNS-derived α-synuclein aggregates appears to be
independent of the absolute amount and basic biochem-
ical properties of α-synuclein within these fractions and
may rely instead on differences in α-synuclein con-
formation and/or yet unrecognized brain region-
specific intrinsic factors. The identification of such
factors should shed light on the physiopathological
role of α-synuclein in PD and open new avenues for
therapeutic intervention.
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